Study population and data collection
A single center, retrospective chart review was conducted in which
pediatric patients who met inclusion criteria that were treated with
enoxaparin for VTE (including PE or DVT) over a 10-year period
(2009-2019) were assessed. The study was approved by the Institutional
Review Board at University of New Mexico Hospitals with waiver of
informed consent. Patients were identified by ICD-9 or ICD-10 codes for
VTE, PE, or DVT. Patients were included if they were 2 months to 18
years of age who had received an enoxaparin dose based on the CHEST
guidelines for treatment of VTE and anti-Xa levels drawn to establish
target attainment. Patients were excluded if they were neonates, on
renal replacement therapy, prescribed enoxaparin for VTE prophylaxis,
incomplete data for chart review, or patients who were not managed based
on the CHEST guideline dosing recommendations. The primary objective of
the study was to determine which characteristics led to enoxaparin dose
changes in pediatric patients. The secondary objective was to determine
the mean number of dosing changes needed to reach target level, the mean
number of anti-Xa levels drawn, and explore the number of dose changes
based on the confirmatory, week 1, and month 1 anti-Xa levels. See table
1 for variables analyzed.
Study data were collected and managed using REDCap electronic data
capture tools hosted at the University of New
Mexico.13 REDCap (Research Electronic Data Capture) is
a secure, web-based application designed to support data capture for
research studies, providing 1) an intuitive interface for validated data
entry; 2) audit trails for tracking data manipulation and export
procedures; 3) automated export procedures for seamless data downloads
to common statistical packages; and 4) procedures for importing data
from external sources.